HK1178532A1 - 用作葡糖激酶激活劑的 -氧代- -二氫- -苯並吡喃並 吡咯類化合物 - Google Patents

用作葡糖激酶激活劑的 -氧代- -二氫- -苯並吡喃並 吡咯類化合物

Info

Publication number
HK1178532A1
HK1178532A1 HK13106217.9A HK13106217A HK1178532A1 HK 1178532 A1 HK1178532 A1 HK 1178532A1 HK 13106217 A HK13106217 A HK 13106217A HK 1178532 A1 HK1178532 A1 HK 1178532A1
Authority
HK
Hong Kong
Prior art keywords
chromeno
pyrroles
dihydro
oxo
glucokinase activators
Prior art date
Application number
HK13106217.9A
Other languages
English (en)
Inventor
拉馬凱斯．薩拉布
Original Assignee
霍夫曼-拉羅奇有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 霍夫曼-拉羅奇有限公司 filed Critical 霍夫曼-拉羅奇有限公司
Publication of HK1178532A1 publication Critical patent/HK1178532A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK13106217.9A 2010-06-17 2013-05-27 用作葡糖激酶激活劑的 -氧代- -二氫- -苯並吡喃並 吡咯類化合物 HK1178532A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35561910P 2010-06-17 2010-06-17
PCT/EP2011/059783 WO2011157682A1 (en) 2010-06-17 2011-06-14 3-oxo-3,9-dihydro-1h-chromeno[2,3-c]pyrroles as glucokinase activators

Publications (1)

Publication Number Publication Date
HK1178532A1 true HK1178532A1 (zh) 2013-09-13

Family

ID=44266428

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13106217.9A HK1178532A1 (zh) 2010-06-17 2013-05-27 用作葡糖激酶激活劑的 -氧代- -二氫- -苯並吡喃並 吡咯類化合物

Country Status (11)

Country Link
US (1) US8178689B2 (zh)
EP (1) EP2582706A1 (zh)
JP (1) JP5844355B2 (zh)
KR (1) KR20130120993A (zh)
CN (1) CN102947311B (zh)
BR (1) BR112012032235A2 (zh)
CA (1) CA2801168A1 (zh)
HK (1) HK1178532A1 (zh)
MX (1) MX2012010668A (zh)
RU (1) RU2603191C2 (zh)
WO (1) WO2011157682A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ709362A (en) * 2012-12-25 2019-07-26 Hua Medicine Process for the preparation of 1-([1,3]dioxolan-4-ylmethyl)-1h-pyrazol-3-ylamine
GB201714777D0 (en) 2017-09-14 2017-11-01 Univ London Queen Mary Agent
JP2022512812A (ja) * 2018-10-24 2022-02-07 エフ．ホフマン－ラ ロシュ アーゲー Ｂ型肝炎ウイルス疾患の処置及び予防のための新規三環式化合物

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3442484A (en) 1983-10-18 1985-04-26 E.I. Du Pont De Nemours And Company 8-substituted pyrazolopentathiepins
JPS6284064A (ja) 1985-10-09 1987-04-17 Shionogi & Co Ltd ３−パ−フルオロアルキル−５−ヒドロキシイソオキサゾ−ル類
JPH0477477A (ja) 1990-07-18 1992-03-11 Takeda Chem Ind Ltd チアジアゾール酢酸誘導体の製造法
GB9103454D0 (en) 1991-02-19 1991-04-03 Pfizer Ltd Therapeutic agents
IL103678A (en) 1991-11-13 1996-09-12 Schering Ag History of pyrazolylpyrazole, processes for their preparation and herbicidal preparations containing them
US5498190A (en) 1994-06-27 1996-03-12 Handsontoys, Inc. Flexible foam construction toy and method of manufacturing same
JPH08151386A (ja) 1994-09-27 1996-06-11 Takeda Chem Ind Ltd 複素環エチルチオセフェム化合物、その製造法および抗菌組成物
ATE248186T1 (de) 1998-04-30 2003-09-15 Agouron Pharma Antipicornavirale verbindungen, deren herstellung und verwendung
GB9812523D0 (en) 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
US6610846B1 (en) 1999-03-29 2003-08-26 Hoffman-La Roche Inc. Heteroaromatic glucokinase activators
IL147395A0 (en) 1999-07-15 2002-08-14 Pharmacopeia Inc Bradykinin b1 receptor antagonists
US7329679B2 (en) 2000-01-27 2008-02-12 Schering Aktiengesellschaft 1,2 Diarylbenzimidazoles and their pharmaceutical use
DE60106599T2 (de) 2000-05-08 2006-02-09 F. Hoffmann-La Roche Ag Substituierte phenylacetamide und ihre verwendung als glukokinase aktivatoren
US6482951B2 (en) * 2000-12-13 2002-11-19 Hoffmann-La Roche Inc. Isoindolin-1-one glucokinase activators
GB0112834D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
PT1501815E (pt) 2002-04-26 2007-01-31 Hoffmann La Roche Fenilacetamidas substituídas e a sua utilização como activadores de glicocinase
JP4881559B2 (ja) 2002-06-27 2012-02-22 ノボ・ノルデイスク・エー／エス 治療薬としてのアリールカルボニル誘導体
AU2003287038A1 (en) 2002-10-09 2004-05-04 The Board Of Trustees Of The University Of Illinois METHOD OF PREPARING (3R, 3aS, 6aR) -3- HYDROXYHEXAHYDROFURO (2, 3-b) FURAN AND RELATED COMPOUNDS
MY141521A (en) 2002-12-12 2010-05-14 Hoffmann La Roche 5-substituted-six-membered heteroaromatic glucokinase activators
PL378117A1 (pl) 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
NZ540791A (en) 2003-02-13 2009-09-25 Banyu Pharma Co Ltd Novel 2-pyridinecarboxamide derivatives
US7432287B2 (en) 2003-02-26 2008-10-07 Banyu Pharmeceutical Co., Ltd. Heteroarylcarbamoylbenzene derivative
CA2547591C (en) 2003-10-24 2010-08-17 Aventis Pharmaceuticals Inc. Novel compounds and compositions as cathepsin inhibitors
ATE517622T1 (de) 2003-10-27 2011-08-15 Merck Sharp & Dohme Salz eines tetrahydropyranylcyclopentyltetrahydropyridopyr diderivats als ccr-2 antagonisten
EP2444397A1 (en) 2004-01-06 2012-04-25 Novo Nordisk A/S Heteroaryl-ureas and their use as glucokinase activators
JP2007523905A (ja) 2004-02-18 2007-08-23 アストラゼネカ アクチボラグ 化合物
JP2007529541A (ja) 2004-03-16 2007-10-25 ワイス イオンチャネルモジュレーター
US7687502B2 (en) 2004-03-23 2010-03-30 Banyu Pharmaceutical Co., Ltd. Substituted quinazoline or pyridopyrimidine derivative
TW200600086A (en) 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
KR100672184B1 (ko) * 2004-09-21 2007-01-19 주식회사종근당 파록세틴의 콜린산 또는 콜린산 유도체 염
EP1824835A1 (en) 2004-12-03 2007-08-29 Novo Nordisk A/S Heteroaromatic glucokinase activators
WO2006064286A1 (en) 2004-12-13 2006-06-22 Medivir Uk Ltd Cathepsin s inhibitors
AU2006268708A1 (en) 2005-07-08 2007-01-18 Transtech Pharma Inc. Dicycloalkyl urea glucokinase activators
NZ564743A (en) 2005-07-11 2010-03-26 Mitsubishi Tanabe Pharma Corp An oxime derivative as a glucokinase activating agent and preparations thereof
ES2422383T3 (es) 2005-07-14 2013-09-11 Novo Nordisk As Activadores de urea glucoquinasa
US20090281142A1 (en) 2005-08-31 2009-11-12 Astellas Pharma Inc. Thiazole derivative
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
EP1960385A1 (en) 2005-11-01 2008-08-27 Janssen Pharmaceutica N.V. Substituted dihydroisoindolones as allosteric modulators of glucokinase
TWI411607B (zh) 2005-11-14 2013-10-11 Vitae Pharmaceuticals Inc 天門冬胺酸蛋白酶抑制劑
WO2007061923A2 (en) 2005-11-18 2007-05-31 Takeda San Diego, Inc. Glucokinase activators
US8022222B2 (en) 2006-01-27 2011-09-20 Array Biopharma, Inc. Glucokinase activators
US8022223B2 (en) 2006-03-24 2011-09-20 Array Biopharma, Inc. 2-aminopyridine analogs as glucokinase activators
WO2007115968A2 (en) 2006-04-12 2007-10-18 F. Hoffmann-La Roche Ag Process for the preparation of a glucokinase activator
ES2487967T3 (es) 2006-04-20 2014-08-25 Pfizer Products Inc. Compuestos amido heterocíclicos condensados con fenilo para la prevención y el tratamiento de enfermedades mediadas por la glucoquinasa
US7880012B2 (en) 2006-04-28 2011-02-01 Transtech Pharma, Inc. Benzamide glucokinase activators
EP2049518B1 (en) 2006-05-31 2011-08-31 Takeda San Diego, Inc. Indazole and isoindole derivatives as glucokinase activating agents.
US7888504B2 (en) 2006-07-06 2011-02-15 Bristol-Myers Squibb Company Glucokinase activators and methods of using same
CN101490064B (zh) * 2006-07-06 2012-10-10 百时美施贵宝公司 新颖葡萄糖激酶活化剂及其使用方法
US7910747B2 (en) 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
BRPI0715531A2 (pt) 2006-07-24 2014-06-24 Hoffmann La Roche Composto, composição farmacêutica, método para o tratamento de uma enfermidade e/ou distúrbio metabólico, processo para a preparação de compostos e uso do composto
JP5248477B2 (ja) 2007-03-07 2013-07-31 杏林製薬株式会社 グルコキナーゼ活性化物質
WO2008121602A1 (en) 2007-03-29 2008-10-09 Smithkline Beecham Corporation Chemical compounds
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators

Also Published As

Publication number Publication date
KR20130120993A (ko) 2013-11-05
RU2012156706A (ru) 2014-07-27
US20110313002A1 (en) 2011-12-22
JP5844355B2 (ja) 2016-01-13
EP2582706A1 (en) 2013-04-24
BR112012032235A2 (pt) 2019-09-24
CN102947311B (zh) 2015-11-25
CN102947311A (zh) 2013-02-27
US8178689B2 (en) 2012-05-15
JP2013532146A (ja) 2013-08-15
WO2011157682A1 (en) 2011-12-22
CA2801168A1 (en) 2011-12-22
RU2603191C2 (ru) 2016-11-27
MX2012010668A (es) 2012-10-03

Similar Documents

Publication Publication Date Title
IL254055A0 (en) Cytotoxic benzodiazepine derivatives, preparations containing them and their uses
HRP20182078T1 (hr) Derivati cis-tetrahidro-spiro(cikloheksan-1,1’-pirido[3,4-b]indol)-4-amina
HK1183029A1 (zh) 作為 調節劑的吡唑並 嘧啶和噻吩並 嘧啶衍生物
HK1187606A1 (zh) 取代的 -稠合含氮雜環化合物及其用途
IL232382A0 (en) History of fused pyrimidines, preparations containing them, and their uses
ZA201205788B (en) 1,2,4-triazine-4-amine derivatives
ZA201406148B (en) Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof
HK1164281A1 (zh) 用作葡糖激酶活化劑的苯並呋喃基衍生物
HK1179617A1 (zh) -四氫- 氧氮雜䓬- -基胺或 -四氫- 氧氮雜䓬- -基胺化合物
SG10201706594PA (en) Bicyclic heterocyclic derivatives as mnk1 and mnk2 modulators and uses thereof
ZA201206440B (en) [5,6]heterocyclic compound
EP2635301A4 (en) CYTOTOXIC AGENTS COMPRISING NOVEL ANSAMITOCIN DERIVATIVES
IL214425A (en) Converted metastatic heterocyclic compounds, their pharmaceutical preparations and their uses
AP2011005889A0 (en) Thienopyrimidinedione derivatives as TRPA1 modulators.
AP2011005888A0 (en) Isothiazolo-pyrimidinedione derivatives as TRPA1 modulators.
ZA201206630B (en) Hetaryl-[1,8]naphthyridine derivatives
IL225785A0 (en) Heterocyclic compounds, preparations containing them and their uses
IL221207A0 (en) Pyrazolo piperidine derivatives, compositions comprising the same and uses thereof
IL221209A0 (en) Pyrazolo piperidine derivatives, compositions comprising the same and uses thereof
IL235681A0 (en) 5- amino [1, 4] thiazines as 1 bace inhibitors
ZA201304016B (en) Photochromic compounds, compositions and articles
IL220707A0 (en) 2,5,7-substituted oxazolopyrimidine derivatives
ZA201302112B (en) 1,4-oxazepane derivatives
HK1178532A1 (zh) 用作葡糖激酶激活劑的 -氧代- -二氫- -苯並吡喃並 吡咯類化合物
HK1184786A1 (zh) -二氫- -惡唑並 吡嗪- -二酮的衍生物

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20200616